Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France

IMPORTANCE: ERBB2-low (ie, ERBB2 immunohistochemistry score of 1+ or 2+ in the absence of ERBB2 gene amplification) breast cancer (BC) is a new entity, with emerging dedicated treatments. Little is known about its prognosis and response to conventional therapy compared with ERBB2-zero breast tumors...

Descripción completa

Detalles Bibliográficos
Autores principales: de Calbiac, Ombline, Lusque, Amélie, Mailliez, Audrey, Bachelot, Thomas, Uwer, Lionel, Mouret-Reynier, Marie-Ange, Emile, George, Jouannaud, Christelle, Gonçalves, Anthony, Patsouris, Anne, Diéras, Véronique, Leheurteur, Marianne, Petit, Thierry, Cottu, Paul, Ferrero, Jean-Marc, D'Hondt, Véronique, Desmoulins, Isabelle, Mourato-Ribeiro, Joana, Martin, Anne-Laure, Frenel, Jean-Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478776/
https://www.ncbi.nlm.nih.gov/pubmed/36107428
http://dx.doi.org/10.1001/jamanetworkopen.2022.31170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478776/
https://www.ncbi.nlm.nih.gov/pubmed/36107428
http://dx.doi.org/10.1001/jamanetworkopen.2022.31170

Ejemplares similares